Yahoo Finance | EN590 Commodities
EN590 Commodities GroupMarket Analysis 2026-07-18T13:50:00+00:00
Following an excellent run in June, when the stock rose by more than 19%,Viking Therapeutics(NASDAQ: VKTX) stock recently dipped, potentially creating a buying opportunity for an exciting growth stock with huge potential in the weight-loss drug sector. Is the dip enough to make the stock a buy? According to Visible Alpha, the Wall Street consensus price target for the stock is just below $91, representing a potential 150% return from the current price. The analyst's excitement about the stock stems from its lead drug candidate, VK2735, and its potential in the highly lucrativeweight-lossmarket. Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction
About EN590 Commodities Group
25+ years in mineral exploration and extraction. 15+ years of global commodity trading. Based in New York, USA serving 75+ countries.